New FDA Guidance Aims to Boost Access to Opioid-Reversal Drug

Under new guidance, harm reduction programs distributing naloxone will be exempt from certain federal requirements in an effort to increase access to the opioid antidote.
Medscape Medical News

source https://www.medscape.com/viewarticle/982472?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension